Patent Listing Review Should Be FDA Function, Rep. DeLauro Suggests
Executive Summary
FDA should review patents before they are listed in the "Orange Book," members of the House Agriculture Appropriations Subcommittee suggested March 21
You may also be interested in...
Rockefeller Generic Rx Bill Would Penalize Brands For Failed Patent Defense
Generic drug legislation floated by Sen. Jay Rockefeller (D-W.Va.) would create a drug reimbursement fund to compensate parties denied access to generic drugs due to litigation
Rockefeller Generic Rx Bill Would Penalize Brands For Failed Patent Defense
Generic drug legislation floated by Sen. Jay Rockefeller (D-W.Va.) would create a drug reimbursement fund to compensate parties denied access to generic drugs due to litigation
Rx Patent Litigation Relates Mostly To Formulation, Use Patents, FTC Says
A majority of drug patent challenges involve patents that do not cover the active ingredient, Federal Trade Commission Chairman Timothy Muris told a Senate Commerce Committee hearing on generic drugs April 23